Stocks › NBIX
NEUROCRINE BIOSCIENCES INC
NBIX·Nasdaq·
United States·USD
$150.57
-6.02 (-3.84%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
NBIX
NEUROCRINE BIOSCIENCES INC · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
NBIXS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of NBIX by members of U.S. Congress · 28 on record
Whale Activity
Position changes in NBIX reported for 2026-09-30 by 871 institutional filers
- Increased301
- New100
- Held88
- Decreased255
- Closed97
- No prior filing30
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 14.9M | $2.11B | increased |
| DODGE & COX | 5.5M | $780.8M | decreased |
| JPMORGAN CHASE & CO | 5.3M | $733.0M | decreased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5.1M | $717.7M | increased |
| STATE STREET CORP | 4.8M | $682.0M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.6M | $649.7M | increased |
| AQR CAPITAL MANAGEMENT LLC | 3.1M | $422.5M | decreased |
| Vestal Point Capital, LP | 2.5M | $354.6M | increased |
| RENAISSANCE TECHNOLOGIES LLC | 2.3M | $326.3M | decreased |
| GEODE CAPITAL MANAGEMENT, LLC | 2.1M | $301.0M | decreased |
| BNP Paribas Asset Management Holding S.A. | 1.5M | $215.9M | — |
| MORGAN STANLEY | 1.4M | $204.8M | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Net shares bought (+) or sold (−) on the open market by NBIX insiders, by quarter · Form 4
Recent Insider Transactions
1,754 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| LYONS GARY ADirector · Director | Sale | −5,689 | $165.15 | $940K | Nov 17, 2026 | Form 4 ↗ |
| LYONS GARY ADirector · Director | Sale | −4,100 | $165.90 | $680K | Nov 17, 2026 | Form 4 ↗ |
| LYONS GARY ADirector · Director | Sale | −4,011 | $163.94 | $658K | Nov 17, 2026 | Form 4 ↗ |
| LYONS GARY ADirector · Director | Sale | −1,200 | $163.11 | $196K | Nov 17, 2026 | Form 4 ↗ |
| MORROW GEORGE JDirector · Director | Sale | −908 | $165.71 | $150K | Nov 3, 2026 | Form 4 ↗ |
| MORROW GEORGE JDirector · Director | Sale | −600 | $163.71 | $98K | Nov 3, 2026 | Form 4 ↗ |
| MORROW GEORGE JDirector · Director | Sale | −1,500 | $167.72 | $252K | Nov 3, 2026 | Form 4 ↗ |
| MORROW GEORGE JDirector · Director | Sale | −1,466 | $166.77 | $244K | Nov 3, 2026 | Form 4 ↗ |
| MORROW GEORGE JDirector · Director | Sale | −1,300 | $168.53 | $219K | Nov 3, 2026 | Form 4 ↗ |
| MORROW GEORGE JDirector · Director | Sale | −1,226 | $164.74 | $202K | Nov 3, 2026 | Form 4 ↗ |
| MORROW GEORGE JDirector · Director | Sale | −100 | $162.05 | $16K | Nov 3, 2026 | Form 4 ↗ |
| MORROW GEORGE JDirector · Director | Sale | −100 | $158.18 | $16K | Nov 3, 2026 | Form 4 ↗ |
| MORROW GEORGE JDirector · Director | Sale | −4,300 | $145.86 | $627K | Nov 2, 2026 | Form 4 ↗ |
| MORROW GEORGE JDirector · Director | Sale | −1,900 | $144.98 | $275K | Nov 2, 2026 | Form 4 ↗ |
| MORROW GEORGE JDirector · Director | Sale | −1,300 | $146.76 | $191K | Nov 2, 2026 | Form 4 ↗ |
| MORROW GEORGE JDirector · Director | Sale | −300 | $149.00 | $45K | Oct 30, 2026 | Form 4 ↗ |
| Boyer David W.Chief Corp. Affairs Officer | Sale | −826 | $157.45 | $130K | Sep 14, 2026 | Form 4 ↗ |
| ABERNETHY MATTChief Financial Officer | Sale | −2,311 | $157.20 | $363K | Sep 14, 2026 | Form 4 ↗ |
| Delaet IngridChief Regulatory Officer | Tax withholding | −2,419 | $156.22 | $378K | Sep 11, 2026 | Form 4 ↗ |
| Delaet IngridChief Regulatory Officer | Grant / award | +4,483 | $0.00 | $0 | Sep 11, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding NBIX · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| Dodge & Cox Stock Fund Dodge & Cox Funds | 4.0M | $668.1M | 0.56% | Jun 30, 2026 |
| iShares Core S&P Mid-Cap ETF iShares Trust | 3.4M | $579.9M | 0.47% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 3.2M | $538.2M | 0.02% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 2.3M | $388.5M | 0.21% | Jun 30, 2026 |
| JPMorgan Growth Advantage Fund J.P. Morgan Mutual Fund Investment Trust | 1.4M | $229.0M | 1.02% | Jun 30, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 1.3M | $224.1M | 0.48% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.2M | $194.3M | 0.20% | Jun 30, 2026 |
| JPMorgan Mid Cap Growth Fund JPMorgan Trust II | 1.1M | $188.2M | 1.42% | Jun 30, 2026 |
| State Street SPDR S&P MidCap 400SM ETF Trust SPDR S&P MIDCAP 400 ETF TRUST | 773.6K | $130.4M | 0.46% | Jun 30, 2026 |
| iShares Biotechnology ETF iShares Trust | 700.1K | $118.0M | 1.30% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list NBIX's shares (CUSIP 64125C109), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- Vanguard Portfolio ManagementSCHEDULE 13G · passive (13G) · 5.1M shares5.0%
Oct 30, 2026 · ↗ - JPMORGAN CHASE & CO.SCHEDULE 13G/A · passive (13G) · 5.3M shares5.2%
Oct 15, 2026 · ↗ - JPMORGAN CHASE & CO.SCHEDULE 13G/A · passive (13G) · 6.3M shares6.3%
Jul 27, 2026 · ↗ - Vanguard Capital ManagementSCHEDULE 13G · passive (13G) · 5.3M shares5.2%
Apr 30, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming neurocrine biosciences as client
- TARPLIN, DOWNS & YOUNG, LLCNEUROCRINE BIOSCIENCES, INC. · 2026 Q3 · HCR, MMM, BUD$110K
Filing ↗ - BGR GOVERNMENT AFFAIRSNEUROCRINE BIOSCIENCES, INC. · 2026 Q3 · PHA$60K
Filing ↗ - NEUROCRINE BIOSCIENCES, INCNEUROCRINE BIOSCIENCES, INC · 2026 Q3 · MMM, HCR, BUD, TAX$940K
Filing ↗ - CAPITOL COUNSEL LLCNEUROCRINE BIOSCIENCES, INC. · 2026 Q3 · BUD, HCR, MMM$60K
Filing ↗ - BGR GOVERNMENT AFFAIRSNEUROCRINE BIOSCIENCES, INC. · 2026 Q2 · PHA$60K
Filing ↗
Government Contracts
Federal awards to NEUROCRINE BIOSCIENCES INC · USAspending
No federal contract awards found for NEUROCRINE BIOSCIENCES INC.
U.S. Patents
Recent USPTO applications naming NEUROCRINE BIOSCIENCES INC
No USPTO patent applications found for NEUROCRINE BIOSCIENCES INC.
Annual Financials
From NBIX's 10-K filings · XBRL
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B |
| Operating income | $619.1M | $570.5M | $250.9M | $249.0M | $102.5M |
| Net income | $478.6M | $341.3M | $249.7M | $154.5M | $89.6M |
| Diluted EPS | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 |
| Operating cash flow | $782.7M | $595.4M | $389.9M | $339.4M | $256.5M |
| Cash and equivalents | $713.0M | $233.0M | $251.1M | $262.9M | $340.8M |
| Total assets | $4.63B | $3.72B | $3.25B | $2.37B | $2.07B |
| Total liabilities | $1.38B | $1.13B | $1.02B | $660.9M | $698.5M |
| Shareholders' equity | $3.25B | $2.59B | $2.23B | $1.71B | $1.37B |
As NEUROCRINE BIOSCIENCES INC tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 11, 2026 ↗
Stock Splits
Every split and reverse split in the price history
No stock splits in NBIX's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 2.02, 9.01Results of operationsNov 2, 2026
EDGAR ↗ - 8-K · Items 5.02Officer / director changeSep 28, 2026
EDGAR ↗ - 8-K/A · Items 9.01Jul 31, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsJul 30, 2026
EDGAR ↗ - 8-K · Items 5.02, 5.07Officer / director change · Shareholder voteMay 28, 2026
EDGAR ↗ - 8-K · Items 1.01, 2.01, 2.03, 7.01, 9.01Material agreement · Acquisition or disposition · Direct financial obligationMay 18, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 5, 2026
EDGAR ↗
About NEUROCRINE BIOSCIENCES INC
From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersSAN DIEGO, CA
IncorporatedDE
SEC CIK0000914475 ↗




